Telehealth Weight Loss/GLP-1 Prescribing: What Prescribers Can Do

If you’re a psychiatrist or PMHNP watching the GLP-1 revolution unfold, you’ve probably asked yourself: Should I be prescribing these medications? Your patients are asking about Wegovy and Ozempic. Many of them struggle with medication-induced weight gain from antipsychotics or mood stabilizers. The metabolic-psychiatric connection is undeniable.

Here’s the reality: Yes, psychiatrists can prescribe weight-loss medications, including GLP-1 agonists — but the answer comes with important caveats about scope of practice, state regulations, and clinical competency. This isn’t about chasing a trend; it’s about understanding whether treating obesity fits into comprehensive psychiatric care, and if so, how to do it legally and ethically.

This guide breaks down everything you need to know: the regulatory landscape, state-by-state prescribing rules, reimbursement realities, and how telehealth platforms are making weight management a viable practice expansion for mental health providers.

The Case for Psychiatrists Prescribing Weight-Loss Medications

The Metabolic-Psychiatric Connection

Let’s start with why this question even matters. Traditional medical silos put obesity in the endocrinology or primary care lane. But here’s what’s changed: psychiatric medications are among the leading causes of weight gain in patients taking antipsychotics, mood stabilizers, and certain antidepressants. Olanzapine can add 10-20 pounds in months. Clozapine and valproate aren’t much better.

For years, psychiatrists have monitored metabolic panels and managed side effects like hyperglycemia. You’re already addressing the metabolic consequences of your prescriptions — so why not treat them directly?

Dr. Elliott Lewis, a board-certified psychiatrist and obesity medicine specialist, argues that managing weight in psychiatric patients isn’t outside our scope — it’s an extension of comprehensive care:

‘If we truly understand that metabolic and mental health systems are inseparable, then psychiatrists being involved in metabolic treatment makes complete sense. It’s not about expanding scope to grab more patients; it’s about offering more integrated care to the patients we already see.’

The Evidence on GLP-1s and Mental Health

One major concern providers raise: Do these drugs worsen depression or increase suicidality? The data is reassuring.

A 2025 meta-analysis in JAMA Psychiatry found no increase in depression or suicidal ideation with GLP-1 medications versus placebo. In fact, patients on semaglutide showed slightly lower rates of depressive symptoms in the STEP trials compared to controls. Both the FDA and European Medicines Agency reviewed the data after early case reports and concluded there’s no causal link between GLP-1s and psychiatric harm.

Beyond safety, there’s emerging evidence of potential benefits:

• Reduced cravings for alcohol and other substances (GLP-1 receptors are in addiction-related brain regions)
• Improved quality of life scores independent of weight loss
• Better metabolic control, which indirectly improves mood and energy in patients with insulin resistance

The biological rationale: GLP-1 agonists reduce systemic inflammation and may influence neurotransmitter function in ways researchers are still mapping out.

Is This Within a Psychiatrist’s Scope of Practice?

The ‘scope of practice’ question isn’t about your specialty title — it’s about competency. If you gain the requisite knowledge through CME, mentorship, or formal certification, prescribing GLP-1s falls within an acceptable extension of practice.

Consider this: you already prescribe stimulants for ADHD (which affect metabolism), monitor thyroid function, manage lithium-induced kidney issues, and coordinate with primary care on cardiovascular risks. Prescribing a medication to mitigate weight gain from your own prescriptions is arguably more within your wheelhouse than many of those tasks.

One concrete pathway: Obesity Medicine Board Certification. Psychiatrists are eligible to sit for the American Board of Obesity Medicine (ABOM) exam. The process involves ~60 hours of obesity-related CME covering nutritional science, metabolic physiology, and anti-obesity pharmacotherapy, then passing a comprehensive exam. Hundreds of psychiatrists have pursued this dual certification to formalize their expertise in metabolic-psychiatric care.

If you’re not ready for board certification, at minimum:

• Complete CME on GLP-1 pharmacology, contraindications, and monitoring
• Understand when to refer to endocrinology (e.g., suspected Cushing’s, uncontrolled thyroid disease)
• Collaborate or communicate with the patient’s primary care provider
• Document clearly that weight management is part of your treatment plan for the patient’s overall wellbeing

The ethical line: Don’t set up a weight-loss clinic for the general public if you lack training. But managing obesity in your existing psychiatric patients — especially medication-induced weight gain or co-occurring metabolic syndrome? That’s defensible, clinically sound, and increasingly recognized as good practice.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

State-by-State Prescribing Authority: MDs vs PMHNPs

Psychiatrists (MD/DO): Full Authority with State-Specific Rules

The bottom line: Licensed physicians have broad prescriptive authority in all states for FDA-approved weight-loss medications. You can prescribe phentermine (Schedule IV), GLP-1 agonists like semaglutide or tirzepatide, orlistat, and other approved agents.

However, individual states impose clinical standards and practice requirements:

Florida sets the gold standard for strict oversight:

• Patients must have BMI ≥30 (or ≥27 with comorbidity) documented before prescribing
• Comprehensive physical exam required before initiating treatment (can be delegated to APRN/PA but must be thorough)
• Written informed consent mandatory
• Follow-up visits every 3 months minimum while on medication
• Patients must receive Florida’s ‘Weight-Loss Consumer Bill of Rights’ brochure
• Board rule (64B15-14.004) applies to all physicians prescribing obesity drugs

New Jersey requires:

• Complete history and physical exam
• Assessment and treatment/stabilization of psychiatric conditions before or alongside weight-loss meds
• Nutritional counseling and exercise recommendations (not just pills)
• Appropriate lab workup to rule out secondary causes

Virginia mandates:

• Initial exam with diet/exercise plan documented
• Follow-up within 30 days of starting medication
• Monthly visits for the first few months

Mississippi took the unusual step of banning off-label GLP-1 use for weight loss (as of August 2023) — physicians must use FDA-approved obesity formulations (Wegovy, not Ozempic for non-diabetics) or face discipline.

Most states don’t have explicit obesity treatment regulations, but you’re expected to follow standard of care: appropriate workup, informed consent, regular monitoring, and documentation of medical necessity (BMI criteria).

PMHNPs and Nurse Practitioners: It Depends Where You Practice

NP prescribing authority for weight-loss medications is a patchwork. Your ability to prescribe independently, or at all, depends entirely on your state’s Nurse Practice Act.

Full Practice Authority (FPA) States (~24 states + DC):In states like Washington, New Mexico, and soon California (2026), experienced NPs can practice and prescribe independently without physician oversight. In these states, a PMHNP can prescribe GLP-1s and other weight-loss medications autonomously — but you must practice within your competency. Psychiatric NPs are trained in mental health, not metabolic disorders, so you’d want additional education/training to do this responsibly.

Reduced/Collaborative Practice States:States like New York, Illinois, and Pennsylvania require some level of physician collaboration, especially for prescribing.

• New York: NPs need a collaborative agreement initially, but after 3,600 hours of practice can apply for independent status. Even then, you’d want to document competency in weight management.

• Illinois: Offers FPA to NPs with ≥4,000 hours of clinical experience and 250+ hours of continuing education. Illinois APRNs with FPA can prescribe controlled substances (including phentermine) independently, though Schedule II prescribing has additional requirements.

• Pennsylvania: All NPs must have a collaboration agreement with a physician. The collaborating MD’s name appears on prescriptions alongside the NP’s. The agreement must specify which medications the NP can prescribe.

Restricted Practice States:Texas and Florida require mandatory physician oversight for all NP prescribing.

• Texas: Every NP must have a Prescriptive Authority Agreement (PAA) with a Texas-licensed physician. The PAA must detail the scope of prescribing, require monthly quality review meetings, and limit one physician to supervising 7 NPs maximum. For weight-loss prescribing, the PAA should explicitly authorize obesity medications.

• Florida: APRNs must work under written protocols with a supervising physician. Florida’s ‘Autonomous APRN’ pathway exists but excludes psychiatric NPs and still prohibits independent controlled substance prescribing. Bottom line: Florida PMHNPs cannot prescribe weight-loss drugs independently.

The Practical Reality for NPs

Even in full-practice states, you may encounter insurance and pharmacy barriers. Some payers require physician involvement for high-cost GLP-1 prescriptions even when not legally required. Pharmacies sometimes push back on NP prescriptions for expensive medications.

Many telehealth platforms solve this by having physician medical directors available in every state, both for regulatory compliance and to smooth insurance credentialing. This isn’t about NPs being ‘less than’ — it’s about navigating a system that still hasn’t fully caught up to expanded NP scope.

Specialty scope consideration: As a PMHNP, you’re trained in psychiatric care. Prescribing weight-loss medications to your existing patients (especially for medication-induced weight gain) is defensible. Opening a standalone weight-loss clinic for the general public without additional training or collaboration? That’s where state boards might raise questions about practicing outside your specialty scope.

Telehealth Prescribing: The Federal-State Compliance Trap

Telehealth revolutionized access to weight-loss treatment, but providers must navigate a maze of conflicting federal and state rules — especially for controlled substances.

The Federal Landscape: Extended Through 2025

During COVID-19, the DEA waived the Ryan Haight Act’s in-person exam requirement for controlled substance prescribing. That waiver has been extended through December 31, 2025 (fourth extension as of late 2024), allowing providers nationwide to prescribe Schedule II-V medications via telehealth without an initial in-person visit.

This applies to phentermine (Schedule IV appetite suppressant) and other controlled weight-loss drugs. The DEA requires only that you conduct an adequate evaluation via telemedicine and comply with all other CSA requirements (proper registration, recordkeeping, state law).

But here’s the trap: The DEA explicitly states that teleprescribing is only permitted if state law also allows it. And many states have stricter rules than federal law.

State Telehealth Restrictions You Must Know

Florida — The ‘No Remote Phentermine’ State:Florida statute prohibits prescribing controlled substances via telehealth except for specific exceptions: psychiatric disorders, inpatient/hospice care, or emergency addiction treatment. Weight loss isn’t listed.

What this means: You cannot prescribe phentermine via telehealth to Florida patients, even though federal DEA rules allow it. Violating this could result in discipline from the Florida Board of Medicine.

The workaround: GLP-1 agonists (semaglutide, tirzepatide) are not controlled substances, so they CAN be prescribed via telehealth in Florida as long as you meet the state’s obesity treatment standards (BMI documentation, informed consent, quarterly follow-ups).

Alabama, Idaho, South Carolina: Similar restrictions requiring in-person exams for controlled substances. About 8 states maintain telehealth barriers despite federal waivers.

42 states align with federal flexibility and permit teleprescribing of controlled substances during the waiver period. But you must check your specific state’s medical board rules.

Establishing a Valid Patient Relationship

Even where telehealth prescribing is allowed, you must conduct an appropriate evaluation. Most states recognize that a video consultation can establish a doctor-patient relationship equivalent to in-person, but there are standards:

• Texas: Requires a synchronous audiovisual consultation before prescribing via telemedicine
• Florida: Technically allows asynchronous methods by statute, but for weight management the clinical standard requires at least a visual exam (video visit)
• All states: You must document a comprehensive history, review of systems, and assessment sufficient to support the prescription

Enforcement example: In May 2023, a Mississippi physician’s license was suspended for prescribing Ozempic through an instant-messaging platform with no audio/video. The board deemed it failure to establish a proper patient relationship.

Best practice: Initial visit should be by video to visually assess the patient, review vital signs (even if self-reported with photo documentation), and ensure you can defend the clinical decision. Follow-ups can sometimes be phone or secure message if clinically appropriate and state law permits.

Required Monitoring and PDMP Checks

Almost every state requires checking the Prescription Drug Monitoring Program (PDMP) before prescribing controlled substances:

• Florida: E-FORCSE check required before each controlled substance prescription
• Texas: PMP check required for opioids, benzos, barbiturates, and carisoprodol (good practice for phentermine too)
• New York: I-STOP database check required for all Schedule II-IV prescriptions

Telehealth platforms often integrate PDMP checks into their EMR workflow. Don’t skip this — it’s both a legal requirement and crucial for patient safety (identifying doctor shopping or polypharmacy risks).

Compounded Semaglutide: Proceed with Caution

Some telehealth clinics started offering compounded semaglutide to reduce costs. The FDA and state boards are cracking down:

• Alabama Board of Medical Examiners warned in 2023 that using semaglutide sodium (a non-FDA-approved salt form) or non-pharmaceutical grade ingredients is prohibited
• Compounding is only legal when there’s a genuine shortage and the compound uses FDA-sanctioned ingredients from registered facilities

If you’re prescribing compounded GLP-1s, ensure your pharmacy partner is fully compliant. You could face liability for aiding distribution of unlawful compounds, even if you didn’t directly compound the drug.

The Economics: Reimbursement and Revenue Reality

Insurance Coverage Is Expanding Rapidly

The old reality: Weight-loss drugs were largely excluded from insurance coverage. Patients paid $1,000-1,500/month out of pocket for GLP-1s.

The new reality (2025-2026): The landscape is transforming:

Medicare: After years of exclusion, Medicare announced in November 2025 that it will begin covering FDA-approved anti-obesity medications like Wegovy and Mounjaro. Implementation begins in 2026. This is a game-changer — opening treatment to millions of seniors who previously couldn’t afford these medications.

Commercial Insurance: Most major carriers now cover GLP-1 weight-loss medications with prior authorization:

• Requires documented BMI ≥30 (or ≥27 with comorbidity)
• Evidence of lifestyle modification attempts (diet, exercise programs)
• Often requires documentation of a comprehensive weight management plan (not just pills)

Prior authorization forms ask you to attest to the patient’s BMI, comorbidities (diabetes, hypertension, sleep apnea), and previous weight-loss attempts. Be prepared to complete these — they’re tedious but necessary for coverage.

Quantity limits: Some insurers impose initial 30-day supply limits for GLP-1s to monitor adherence and tolerance before approving refills. You may need to follow up monthly initially to justify continuation.

Medicaid: Coverage varies by state. Some state Medicaid programs already cover obesity medications; others are expanding following Medicare’s lead. Check your state’s Medicaid formulary.

What You Can Bill and What It Pays

For the clinical visit:

• Use standard E/M codes (99202-99215 for outpatient visits) based on complexity
• Psychiatrists: Bill at 100% of physician fee schedule (~$100-150 for a typical med management visit)
• PMHNPs: Medicare reimburses at 85% of physician rates; some private insurers pay 85-100%
• Illinois exception: Illinois Medicaid pays APRNs at 100% of physician rates

Obesity counseling codes:

• G0447: 15 minutes of face-to-face behavioral counseling for obesity (BMI ≥30)
• Mainly used by primary care and dietitians, but psychiatrists could bill if providing nutritional counseling

Telehealth modifiers: Add modifier 95 or GT (depending on payer) or use Place of Service code 02 to indicate telehealth delivery.

Telehealth payment parity: Many states require insurers to reimburse telehealth visits at the same rate as in-person:

• California: Telehealth parity law effective 2021
• New York: Mandatory parity for state-regulated plans
• Illinois: Strong telehealth parity via Telehealth Alignment Act
• Texas: Coverage parity mandated but payment parity still being phased in

Medicare continues reimbursing telehealth visits at office (non-facility) rates through at least end of 2025, likely extended into 2026.

The Revenue Math

A well-structured weight management service can be financially sustainable:

Per patient, per month:

• Initial 45-min evaluation: ~$150-200 (99204-99205 or psychiatric eval code)
• Monthly 15-min follow-ups: ~$75-120 (99213-99214)
• Medication cost (if covered by insurance): Patient copay only
• If patient pays cash for uncovered meds: $1,000-1,500/month (they’re seeking alternatives like compounded versions or savings programs)

Volume considerations: If you see 20 weight management patients/month with monthly follow-ups, that’s ~$1,500-2,400 in visit revenue monthly (not counting initial evals). Add medication management fees if you’re dispensing or coordinating pharmacy, though most providers don’t directly profit from the drugs.

The platform advantage: Joining a telehealth platform like Klarity removes the marketing burden entirely. Instead of spending $3,000-5,000/month gambling on Google Ads or SEO (which might yield 5-10 qualified leads if you’re lucky), you pay only when a qualified patient books. No upfront marketing spend. No wasted clicks. Just pre-qualified patients matched to your availability and specialty.

Documentation and Diagnosis Coding

ICD-10 codes for obesity:

• E66.01: Morbid obesity due to excess calories (BMI ≥40)
• E66.09: Other obesity due to excess calories (BMI 30-39.9)
• E66.3: Overweight (BMI 25-29.9, use for patients with comorbidities qualifying for treatment)

List obesity as the primary diagnosis when the visit is predominantly for weight management. This facilitates insurance coverage for both the visit and medication.

Document thoroughly:

• BMI calculation with height/weight
• Comorbidities (diabetes, hypertension, dyslipidemia, sleep apnea)
• Previous weight-loss attempts
• Discussion of risks/benefits, side effects
• Nutritional counseling and exercise recommendations provided
• Monitoring plan (labs, follow-up schedule)

This documentation protects you in audits and meets state requirements (like Florida’s mandatory elements).

State-Specific Guidance for Priority Markets

California

• NP Status: Transitioning to FPA via AB 890; full independence for ‘104’ NPs starts January 2026
• Physician Requirement: Corporate Practice of Medicine doctrine requires MD/DO ownership or medical director structure
• Prescribing: Psychiatrists have full authority; NPs can prescribe under protocols now, independently soon
• Telehealth: No special restrictions; telehealth parity law ensures equal reimbursement
• Market: High demand in urban centers; many cash-pay telehealth clinics operate via MSO structures

Texas

• NP Status: Strict delegation state; all NPs require Prescriptive Authority Agreement with TX physician
• Physician Requirement: Medical directors must be TX-licensed; CPM law mandates physician control
• Prescribing: No Schedule II stimulants for weight loss; phentermine and GLP-1s allowed with proper indication
• Telehealth: Permitted with adequate evaluation; PMP check required for controlled substances
• Compliance: Monthly MD-NP meetings required; one physician may supervise max 7 NPs
• Market: High obesity rate (~35%); robust telehealth activity but close regulatory scrutiny

Florida

• NP Status: APRNs require physician supervision; autonomous practice excludes PMHNPs
• Physician Requirement: Health Care Clinic Act requires MD medical director for weight-loss clinics
• Prescribing: Strict BMI criteria (≥30 or ≥27+comorbidity); quarterly follow-ups mandatory; informed consent required
• Telehealth: Cannot prescribe controlled substances via telehealth (phentermine prohibited remotely); GLP-1s allowed
• PDMP: E-FORCSE check required before each controlled Rx
• Compliance: Vigilant enforcement; expect possible inspections
• Market: High demand but heavily regulated; many providers use physician collaboration services

New York

• NP Status: Reduced practice; independent after 3,600 hours with proper attestation
• Prescribing: No special obesity regulations; follow standard of care
• Telehealth: Very supportive; telehealth payment parity mandated for commercial plans
• PDMP: I-STOP check required for all Schedule II-IV prescriptions
• Market: NYC has many boutique weight-loss clinics; telehealth extending to upstate and rural areas

Pennsylvania

• NP Status: Collaborative practice required; no FPA yet
• Physician Requirement: Collaboration agreement must specify prescribing authority; prescriptions show both MD and NP names
• Prescribing: No special state obesity rules beyond standard practice
• Telehealth: Allowed; limited parity law (mental health parity via Act 69, but not all services)
• Market: Provider shortages in rural areas make telehealth attractive; securing collaborating docs can be challenge

Illinois

• NP Status: Partial FPA available after ≥4,000 hours experience + education
• Prescribing: FPA APRNs can prescribe independently including controlled substances (with Schedule II caveats)
• Reimbursement: Illinois Medicaid pays APRNs 100% of physician rates — rare and valuable
• Telehealth: Strong parity laws; no special restrictions
• PDMP: Required for controlled substances; separate IL controlled substance license needed
• Market: Obesity rate ~32%; major insurers cover GLP-1s with PA

How to Get Started: Practical Steps

1. Assess Your Competency and Training Needs

Minimum:

• Complete CME on GLP-1 pharmacology, contraindications, side effect management
• Review obesity medicine guidelines (Endocrine Society, Obesity Medicine Association)
• Understand when to refer (uncontrolled endocrine disorders, surgical candidates)

Ideal:

• Pursue ABOM certification (60 hours CME + exam)
• Complete formal obesity medicine training program
• Establish consultation relationships with endocrinology and bariatric surgery

2. Verify State-Specific Requirements

• Check your state’s medical/nursing board rules on obesity treatment
• Understand NP collaboration requirements if applicable
• Review telehealth prescribing restrictions (especially for controlled substances)
• Register for PDMP access in states where you’ll practice

3. Set Up Clinical Protocols

Initial evaluation should include:

• Comprehensive history (weight history, previous attempts, eating patterns)
• Psychiatric screening (depression, eating disorders, substance use)
• Physical assessment (BMI, blood pressure, waist circumference)
• Labs: CBC, CMP, lipid panel, HbA1c, TSH, vitamin D (baseline)
• EKG if considering phentermine (cardiac contraindications)

Follow-up protocol:

• Monthly initially (first 3 months) to monitor tolerance and titrate dose
• Quarterly thereafter (minimum in states like Florida)
• Document weight, blood pressure, side effects, medication adjustments
• Re-evaluate labs every 6-12 months

Red flags requiring specialist referral:

• Unintentional weight loss
• Suspected Cushing’s syndrome or other endocrine disorder
• Severe psychiatric decompensation (suicidal ideation, though not caused by GLP-1s)
• Gallbladder disease (GLP-1 side effect)
• Pancreatitis symptoms

4. Navigate Insurance and Prior Authorizations

• Credential with major insurance plans (or join platform with existing contracts)
• Learn each payer’s PA requirements for GLP-1s
• Keep documentation templates ready (BMI calculation, comorbidity checklist, lifestyle modification documentation)
• Inform patients about potential coverage gaps and cash-pay options

5. Consider Platform vs Solo Practice

Building solo telehealth practice:

• Pros: Full control, keep all revenue
• Cons: Need to handle marketing ($3,000-5,000/month minimum for ads/SEO), credentialing, billing, compliance across states
• Reality check: SEO takes 6-12 months to generate meaningful traffic. Google Ads for ‘weight loss psychiatrist’ cost $15-40/click with poor conversion (10-20 clicks per booked patient = $150-800 acquisition cost). Psychology Today and Zocdoc charge monthly fees plus per-booking fees ($35-100). Total monthly marketing spend for marginal results can hit $5,000+ before you see ROI.

Joining a platform like Klarity:

• Pros: Pre-qualified patients matched to your availability; no marketing spend; built-in telehealth infrastructure; insurance credentialing handled; pay only per appointment
• Cons: Platform fee per patient (but eliminates all other overhead)
• Economics: Standard listing fee per new patient lead vs gambling thousands on uncertain marketing channels. Guaranteed ROI — you pay only when you see patients. No wasted ad budget.

For most providers, especially those starting out or scaling beyond their local market, the platform model removes financial risk entirely. You can start seeing patients next week instead of waiting 6-12 months for your SEO to maybe pay off.

FAQ

Can psychiatrists legally prescribe GLP-1 medications like Wegovy or Ozempic?

Yes, psychiatrists (MD/DO) have full prescriptive authority for FDA-approved weight-loss medications in all states. GLP-1 agonists are not controlled substances, so there are no DEA restrictions beyond your general license. However, you should practice within your competency — additional training in obesity medicine is recommended, and you must follow any state-specific clinical guidelines (like Florida’s BMI documentation and follow-up requirements).

Do I need board certification in obesity medicine to prescribe weight-loss drugs?

No, board certification isn’t legally required. However, pursuing American Board of Obesity Medicine (ABOM) certification strengthens your scope-of-practice legitimacy, demonstrates competency to insurers and patients, and provides comprehensive training in metabolic physiology and anti-obesity pharmacotherapy. Many psychiatrists are obtaining dual certification to formalize their expertise in metabolic-psychiatric care.

Can PMHNPs prescribe weight-loss medications independently?

It depends on your state. In full-practice authority states (like Washington, New Mexico, and Illinois after 4,000 hours), experienced NPs can prescribe independently. In reduced-practice states (New York, Pennsylvania), you need physician collaboration agreements. In restricted states (Texas, Florida), mandatory physician oversight is required. Even in FPA states, you should practice within your specialty competency — consider additional obesity medicine training if expanding beyond medication-induced weight gain management.

Can I prescribe phentermine via telehealth?

Federally yes (through December 2025 DEA waiver), but some states prohibit it. Florida specifically bans controlled substance prescribing via telehealth except for psychiatric disorders (weight loss doesn’t qualify). Alabama, Idaho, and South Carolina have similar restrictions. About 42 states align with federal flexibility and permit it. You must check your specific state’s telehealth laws and medical board rules before prescribing any controlled substance remotely.

What are the required follow-up intervals for patients on weight-loss medications?

State requirements vary. Florida mandates face-to-face follow-up at least every 3 months. Virginia requires follow-up within 30 days of starting medication, then monthly for the first few months. Most states don’t specify intervals but expect you to follow standard of care — monthly visits initially for dose titration and side effect monitoring, then quarterly once stable is typical practice.

Does insurance cover GLP-1 medications for weight loss?

Increasingly yes. Medicare begins covering FDA-approved anti-obesity medications in 2026 (major policy shift). Most commercial insurers cover GLP-1s like Wegovy with prior authorization requiring documented BMI ≥30 (or ≥27 with comorbidity), previous lifestyle modification attempts, and comprehensive weight management plan. Medicaid coverage varies by state. Prior authorizations are tedious but necessary for coverage approval.

How much can I bill for weight management visits?

Use standard E/M codes based on complexity. Typical reimbursement: initial 45-minute evaluation codes (99204-99205) pay ~$150-200; routine 15-minute follow-ups (99213-99214) pay ~$75-120 from Medicare. Psychiatrists bill at 100% of physician fee schedule. PMHNPs receive 85% from Medicare (but 100% in Illinois Medicaid). Many states have telehealth payment parity laws ensuring equal reimbursement for video visits.

What are the main side effects of GLP-1s I should monitor?

Most common: nausea, vomiting, diarrhea (usually mild and resolve with titration). Serious but rare: pancreatitis (abdominal pain), gallbladder disease, kidney injury (from dehydration due to GI symptoms). Contraindications: personal/family history of medullary thyroid cancer or MEN2 syndrome. Good news for psychiatrists: no increased risk of depression or suicidality per 2025 meta-analysis — in fact, slight decrease in depressive symptoms in clinical trials.

Do I need a collaborating physician if I’m an experienced PMHNP wanting to add weight management?

If you’re in a state requiring collaboration (Texas, Florida, Pennsylvania, non-FPA NPs in NY/IL), yes — and your collaboration agreement should explicitly authorize weight-loss prescribing. Even in FPA states, consider at minimum a consulting relationship with an obesity medicine specialist or endocrinologist for complex cases. Psychiatric NPs should also document additional training/competency in obesity treatment since it’s outside standard PMHNP curriculum.

How do telehealth platforms like Klarity handle the compliance complexity across states?

Reputable platforms ensure providers are licensed in the states where they see patients, integrate PDMP checks into workflows, maintain compliance with state-specific prescribing rules (e.g., not offering phentermine via telehealth in Florida), and handle insurance credentialing. They also typically have physician medical directors available to provide oversight in states requiring it. The platform model removes the burden of navigating 50 different state regulations solo.

The Bottom Line: A Growth Opportunity Grounded in Patient Care

Can psychiatrists prescribe weight-loss medications? Yes — and many should consider it as part of comprehensive psychiatric care.

The convergence of metabolic and mental health is undeniable. Your patients struggle with medication-induced weight gain, insulin resistance from antipsychotics, and the psychological toll of obesity. GLP-1 agonists are safe (no psychiatric contraindications based on current evidence), effective, and increasingly covered by insurance.

If you pursue this path:

• Get proper training (CME at minimum, ABOM certification ideally)
• Follow your state’s specific regulations religiously
• Practice within your competency and collaborate when appropriate
• Document thoroughly (BMI, informed consent, monitoring plans)
• Focus on holistic care (nutrition, exercise, behavioral health) not just prescribing

The economics make sense: expanding insurance coverage, telehealth payment parity in most states, and platforms that eliminate marketing risk by providing pre-qualified patients. Instead of gambling $5,000/month on Google Ads with uncertain ROI, you can join a platform and pay only when you see patients.

For PMHNPs, understand your state’s scope limitations and collaboration requirements. In many states you’ll need physician partnership — but that’s manageable and increasingly part of team-based care models.

The field of metabolic psychiatry is emerging. Providers who integrate weight management into their practice now are positioning themselves at the forefront of whole-person psychiatric care — and building a sustainable service line that addresses a massive unmet need.

Ready to expand your practice without the marketing gamble? Klarity Health connects psychiatric providers with pre-qualified patients seeking both mental health care and metabolic management. No upfront costs. No ad spend risk. Just patients who need your expertise, matched to your availability.

Citations

1. MedicalDirector Co. – ‘How Much Does a Collaborative Physician Cost for Weight Loss, Telehealth, and Medspas? (2025 Definitive Guide)’ (Industry compliance guide, 2025) – https://www.medicaldirectorco.com/collaborative-physician-cost-weight-loss-telehealth/

2. MedicalDirector Co. – ‘Florida Weight Loss Clinic and Telehealth Compliance Guide (2025)’ (State-specific legal summary, Updated 2025) – https://www.medicaldirectorco.com/florida-weight-loss-clinic-and-telehealth-compliance-guide-2025/

3. MedicalDirector Co. – *’Texas Weight Loss Clinic & Tele

Source:

• https://www.medicaldirectorco.com/collaborative-physician-cost-weight-loss-telehealth/#:~:text=The%20answer%20is%20almost%20always,yes
• https://www.medicaldirectorco.com/collaborative-physician-cost-weight-loss-telehealth/#:~:text=Nurse%20Practitioners%20
• https://journals.lww.com/tnpj/fulltext/2024/01000/36thannualaprnlegislativeupdate__improving.6.aspx#:~:text=The%20Pennsylvania%20BON%20grants%20CRNPs%2C,more%20physicians%20to%20deliver%20healthcare
• https://journals.lww.com/tnpj/fulltext/2024/01000/36thannualaprnlegislativeupdate__improving.6.aspx#:~:text=The%20Illinois%20Department%20of%20Financial,collaborative%20agreement%20following%20a%20TTP
• https://rxagent.co/blog/telehealth-compliance-trap#:~:text=The%20DEA%20gave%20us%20the,evaluation%20at%20the%20federal%20level
• https://rxagent.co/blog/telehealth-compliance-trap#:~:text=Despite%20federal%20DEA%20waivers%20extending,traps%20for%20digital%20health%20providers
• https://rxagent.co/blog/telehealth-compliance-trap#:~:text=1.%20Florida%3A%20The%20%22No,for%20Stimulants
• https://www.mondaq.com/unitedstates/healthcare/1447512/a-changing-regulatory-and-reimbursement-landscape-for-weight-loss-drugs#:~:text=New%20Jersey%20law%20requires%20that,and%20identify%20the%20risks%20associated
• https://drlewis.com/glp-1-medications-psychiatry/#:~:text=You%20know%20these%20drugs,disorders%2C%20and%20possibly%20depression%20itself
• https://drlewis.com/glp-1-mental-health/#:~:text=Now%20let%E2%80%99s%20talk%20about%20potential,where%20things%20get%20really%20interesting